Efalizumab-associated papular psoriasis: an adverse reaction to efalizumab in three cases.
Efalizumab-associated papular psoriasis is a common adverse event caused by efelizumab therapy. This clinical manifestation is characterized by a transient popular eruption localized especially on the flexural areas and on the back. We report three cases of efalizumab-associated papular psoriasis.
Antonucci
Angela
A
Department of Specialistic and Experimental Clinical Medicine, Division of Dermatology, University of Bologna, Bologna, Italy. av_antonucci@yahoo.it
Bardazzi
Federico
F
Balestri
Riccardo
R
Patrizi
Annalisa
A
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001365:Axilla; D001707:Biopsy, Needle; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology*; D018570:Risk Assessment; D012494:Sampling Studies
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab